China Securities Intelligent Financial News Zhenbao Island (603567) announced on the evening of May 24uggabuggaslotmachineRecently, the company received the "Drug Registration Certificate" for esomeprazole magnesium enteric-coated tablets approved and issued by the State Food and Drug Administration.
According to the announcement, esomeprazole magnesium enteric-coated tablets are proton pump inhibitors that can effectively inhibit gastric acid secretion. They are clinically used in adults with gastroesophageal reflux disease and are used in combination with appropriate antibacterial therapy to eradicate Helicobacter pylori. Patients treated with non-steroidal anti-inflammatory drugs (NSAIDs).
The original manufacturer of esomeprazole magnesium enteric-coated tablets is AstraZeneca, and the trade name is Nexium. The original preparation was approved for marketing in Sweden in March 2000, was approved for import into China (trade name Nexion) in October 2002, and was approved for commercialization on December 9, 2004. At present, except for the company and the original research company of this variety, only two domestic companies of this variety have been approved for listing, and all of them have passed or are deemed to have passed the consistency evaluation.
Eomeprazole magnesium enteric-coated tablets are the fourth batch of national drug collection varieties, national medical insurance Class B drugs. Minet data shows that the total sales of esomeprazole magnesium enteric-coated tablets at terminals of public medical institutions in China and retail terminals of physical pharmacies in key cities in 2022 will be approximately 9%.uggabuggaslotmachine.37 billion yuan, the total sales of terminals in public medical institutions in China in 2023 and retail terminals in physical pharmacies in key cities in the first half of 2023 will be approximately 805 million yuan.
So far, the company has invested 22 million yuan in research and development expenses on the esomeprazole magnesium enteric-coated tablets project.
Zhenbaodao said that this time esomeprazole magnesium enteric-coated tablets have obtained a drug registration certificate, marking that this product has passed the consistency evaluation of generic drugs. The approval of this product enriches the company's product pipeline, enhances the company's market competitiveness, and will have a positive impact on the company's future operating performance.
(Article source: China Securities Journal·China Securities Network)